Abstract
Signal detection is a promising technique used for prompt detection of novel reactions. It is a modern method of detecting new reaction of a drug. Ubrogepant and Rimegepant are calcitonin gene-related peptide (CGRP) receptor antagonists were approved by US Food and Drug Administration (USFDA) in December 2019 and February 2020 respectively for acute treatment of Migraine. This study was to identify the signal strength for Ubrogepant and Rimegepant associated ADRs using data mining technique in USFDA adverse event reporting system (AERS) database.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
